2025 Q3 -tulosraportti
78 päivää sitten
‧36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
100
Myynti
Määrä
2 550
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 732 | NON | NON | ||
| 119 | NON | NON | ||
| 1 560 | NON | NON | ||
| 1 000 | NON | NON | ||
| 15 | NRD | NON |
Ylin
16,45VWAP
Alin
15,35VaihtoMäärä
1,1 66 916
VWAP
Ylin
16,45Alin
15,35VaihtoMäärä
1,1 66 916
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12 t sittenSo March 3rd we'll know more.. or should they present data before they present them,
·15 t sitten · MuokattuThe TD Cowen conference is one of the largest and most prestigious annual health/biotech conferences, where both listed and selected private life science companies present themselves to large investors, funds, analysts, and potential partners. It is a really good opportunity for Curasight to attract attention, new investors, and perhaps even collaborators. This is positive news for the company and us shareholders – they get the chance to showcase their technology on a very visible stage in the industry. So, these are incredibly exciting times ahead! It will be really exciting to follow the company over the next few months, especially as new data from the ongoing Phase 1 with uTREAT® (top-line data expected in Q2 2026) will be released. After 13 years of work as a company (founded in 2013 based on over 10 years of academic research), the pieces are slowly starting to fall into place now. https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454- ·1 päivä sittenJust found an interesting post uploaded on 03-02-2026. Curasight was represented at Theranostics World Congress 2026 (TWC2026) in Cape Town – the global meeting point for theranostics and precision medicine in oncology. Why did Curasight participate? We participated as a delegate through our CMO, prof. Andreas Kjær, to be close to the latest advancements in radiomolecular precision medicine, new radionuclides (such as Tb-161), combination therapies, FAPI-targeting, next-gen PSMA, and dosimetry/AI-driven precision. It is essential for us to follow – and contribute to – the development in the theranostics field, while we ourselves advance our uPAR-platform (uTRACE® for diagnostics + uTREAT® for targeted radiation therapy). Why are we mentioned? The Thera4Care project (a European collaboration with partners such as GE HealthCare, PSI, UK-Essen, SCK CEN, Oncidium, etc.) highlighted Curasight as part of the active delegation at TWC2026. The congress gathered experts from around the world to accelerate translation from research to clinic – and we were there to network, follow presentations, and strengthen our position in the international theranostics environment. Why is this positive? It underscores that Curasight is a visible and relevant player in the global theranostics revolution. With our uPAR-targeting (which targets invasion, angiogenesis, and metastasis across solid tumors), we fit perfectly into the future of precision oncology. Participation gives us insight into trends, new collaboration opportunities, and validation that our approach is on the right track – all for the benefit of patients with aggressive cancers such as glioblastoma and prostate cancer. Link: https://www.thera4care.eu/post/thera4care-at-theranostics-world-congress-2026
- ·2 päivää sittenIn a new article about the radioimmunotherapy market, Curasight is mentioned as one of the players working with the next generation of targeted cancer treatment. This is not price-driving news, but it is still a good signal, because: • The company is placed among large global players • It strengthens international visibility • It supports the narrative of personalized cancer therapy This kind of mention rarely moves the stock in the short term, but it contributes to credibility and visibility 👍🏼 Link: https://www.linkedin.com/pulse/navigating-evolving-landscape-radioimmunotherapy-market-stratorels-okklc?utm_source=share&utm_medium=member_ios&utm_campaign=share_via
- 2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.
·2 päivää sittenExcept that the great performance you link to has subsided and that we are now at 15.1 kr. That post would have made more sense if you had posted it a week ago. Of course, we will probably go up again, but it is also important that we make relevant posts :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
78 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenSo March 3rd we'll know more.. or should they present data before they present them,
- ·15 t sitten · MuokattuThe TD Cowen conference is one of the largest and most prestigious annual health/biotech conferences, where both listed and selected private life science companies present themselves to large investors, funds, analysts, and potential partners. It is a really good opportunity for Curasight to attract attention, new investors, and perhaps even collaborators. This is positive news for the company and us shareholders – they get the chance to showcase their technology on a very visible stage in the industry. So, these are incredibly exciting times ahead! It will be really exciting to follow the company over the next few months, especially as new data from the ongoing Phase 1 with uTREAT® (top-line data expected in Q2 2026) will be released. After 13 years of work as a company (founded in 2013 based on over 10 years of academic research), the pieces are slowly starting to fall into place now. https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454
- ·1 päivä sittenJust found an interesting post uploaded on 03-02-2026. Curasight was represented at Theranostics World Congress 2026 (TWC2026) in Cape Town – the global meeting point for theranostics and precision medicine in oncology. Why did Curasight participate? We participated as a delegate through our CMO, prof. Andreas Kjær, to be close to the latest advancements in radiomolecular precision medicine, new radionuclides (such as Tb-161), combination therapies, FAPI-targeting, next-gen PSMA, and dosimetry/AI-driven precision. It is essential for us to follow – and contribute to – the development in the theranostics field, while we ourselves advance our uPAR-platform (uTRACE® for diagnostics + uTREAT® for targeted radiation therapy). Why are we mentioned? The Thera4Care project (a European collaboration with partners such as GE HealthCare, PSI, UK-Essen, SCK CEN, Oncidium, etc.) highlighted Curasight as part of the active delegation at TWC2026. The congress gathered experts from around the world to accelerate translation from research to clinic – and we were there to network, follow presentations, and strengthen our position in the international theranostics environment. Why is this positive? It underscores that Curasight is a visible and relevant player in the global theranostics revolution. With our uPAR-targeting (which targets invasion, angiogenesis, and metastasis across solid tumors), we fit perfectly into the future of precision oncology. Participation gives us insight into trends, new collaboration opportunities, and validation that our approach is on the right track – all for the benefit of patients with aggressive cancers such as glioblastoma and prostate cancer. Link: https://www.thera4care.eu/post/thera4care-at-theranostics-world-congress-2026
- ·2 päivää sittenIn a new article about the radioimmunotherapy market, Curasight is mentioned as one of the players working with the next generation of targeted cancer treatment. This is not price-driving news, but it is still a good signal, because: • The company is placed among large global players • It strengthens international visibility • It supports the narrative of personalized cancer therapy This kind of mention rarely moves the stock in the short term, but it contributes to credibility and visibility 👍🏼 Link: https://www.linkedin.com/pulse/navigating-evolving-landscape-radioimmunotherapy-market-stratorels-okklc?utm_source=share&utm_medium=member_ios&utm_campaign=share_via
- 2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.·2 päivää sittenExcept that the great performance you link to has subsided and that we are now at 15.1 kr. That post would have made more sense if you had posted it a week ago. Of course, we will probably go up again, but it is also important that we make relevant posts :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
100
Myynti
Määrä
2 550
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 732 | NON | NON | ||
| 119 | NON | NON | ||
| 1 560 | NON | NON | ||
| 1 000 | NON | NON | ||
| 15 | NRD | NON |
Ylin
16,45VWAP
Alin
15,35VaihtoMäärä
1,1 66 916
VWAP
Ylin
16,45Alin
15,35VaihtoMäärä
1,1 66 916
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
2025 Q3 -tulosraportti
78 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenSo March 3rd we'll know more.. or should they present data before they present them,
- ·15 t sitten · MuokattuThe TD Cowen conference is one of the largest and most prestigious annual health/biotech conferences, where both listed and selected private life science companies present themselves to large investors, funds, analysts, and potential partners. It is a really good opportunity for Curasight to attract attention, new investors, and perhaps even collaborators. This is positive news for the company and us shareholders – they get the chance to showcase their technology on a very visible stage in the industry. So, these are incredibly exciting times ahead! It will be really exciting to follow the company over the next few months, especially as new data from the ongoing Phase 1 with uTREAT® (top-line data expected in Q2 2026) will be released. After 13 years of work as a company (founded in 2013 based on over 10 years of academic research), the pieces are slowly starting to fall into place now. https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454
- ·1 päivä sittenJust found an interesting post uploaded on 03-02-2026. Curasight was represented at Theranostics World Congress 2026 (TWC2026) in Cape Town – the global meeting point for theranostics and precision medicine in oncology. Why did Curasight participate? We participated as a delegate through our CMO, prof. Andreas Kjær, to be close to the latest advancements in radiomolecular precision medicine, new radionuclides (such as Tb-161), combination therapies, FAPI-targeting, next-gen PSMA, and dosimetry/AI-driven precision. It is essential for us to follow – and contribute to – the development in the theranostics field, while we ourselves advance our uPAR-platform (uTRACE® for diagnostics + uTREAT® for targeted radiation therapy). Why are we mentioned? The Thera4Care project (a European collaboration with partners such as GE HealthCare, PSI, UK-Essen, SCK CEN, Oncidium, etc.) highlighted Curasight as part of the active delegation at TWC2026. The congress gathered experts from around the world to accelerate translation from research to clinic – and we were there to network, follow presentations, and strengthen our position in the international theranostics environment. Why is this positive? It underscores that Curasight is a visible and relevant player in the global theranostics revolution. With our uPAR-targeting (which targets invasion, angiogenesis, and metastasis across solid tumors), we fit perfectly into the future of precision oncology. Participation gives us insight into trends, new collaboration opportunities, and validation that our approach is on the right track – all for the benefit of patients with aggressive cancers such as glioblastoma and prostate cancer. Link: https://www.thera4care.eu/post/thera4care-at-theranostics-world-congress-2026
- ·2 päivää sittenIn a new article about the radioimmunotherapy market, Curasight is mentioned as one of the players working with the next generation of targeted cancer treatment. This is not price-driving news, but it is still a good signal, because: • The company is placed among large global players • It strengthens international visibility • It supports the narrative of personalized cancer therapy This kind of mention rarely moves the stock in the short term, but it contributes to credibility and visibility 👍🏼 Link: https://www.linkedin.com/pulse/navigating-evolving-landscape-radioimmunotherapy-market-stratorels-okklc?utm_source=share&utm_medium=member_ios&utm_campaign=share_via
- 2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.·2 päivää sittenExcept that the great performance you link to has subsided and that we are now at 15.1 kr. That post would have made more sense if you had posted it a week ago. Of course, we will probably go up again, but it is also important that we make relevant posts :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
100
Myynti
Määrä
2 550
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 732 | NON | NON | ||
| 119 | NON | NON | ||
| 1 560 | NON | NON | ||
| 1 000 | NON | NON | ||
| 15 | NRD | NON |
Ylin
16,45VWAP
Alin
15,35VaihtoMäärä
1,1 66 916
VWAP
Ylin
16,45Alin
15,35VaihtoMäärä
1,1 66 916
Välittäjätilasto
Dataa ei löytynyt